Miriam Paone
14 Papers
14 Citations
Miriam Paone is an academic researcher. The author has contributed to research in topics: Ipilimumab & Melanoma. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone,Diana Giannarelli,Domenico Mallardo,Gabriele Madonna,Lucia Festino,Antonio M. Grimaldi,Vito Vanella,Ester Simeone,Miriam Paone,Giuseppe Palmieri,Ernesta Cavalcanti,Corrado Caracò,Paolo A. Ascierto +12 more
TL;DR: Both Neutrophil-to-lymphocyte ratio (NLR) and derived (d) NLR were associated with improved survival when baseline levels were lower than cut-off values, and NLR and dNLR are simple, inexpensive and readily available biomarkers that could be used to help predict response to immunotherapy in patients with advanced melanoma.
419
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
Antonio M. Grimaldi,Ester Simeone,Diana Giannarelli,Paolo Muto,Sara Falivene,Valentina Borzillo,Francesca Maria Giugliano,Fabio Sandomenico,Antonella Petrillo,Marcello Curvietto,Assunta Esposito,Miriam Paone,Marco Palla,Giuseppe Palmieri,Corrado Caracò,Gennaro Ciliberto,Nicola Mozzillo,Paolo A. Ascierto +17 more
TL;DR: RT after ipilimumab may lead to abscopal responses in some patients with advanced melanoma correlating with prolonged OS, and it is suggested that local responses to RT may be predictive of abscopy responses.
369
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Ester Simeone,Giusy Gentilcore,Diana Giannarelli,Antonio M. Grimaldi,Corrado Caracò,Marcello Curvietto,Assunta Esposito,Miriam Paone,Marco Palla,Ernesta Cavalcanti,Fabio Sandomenico,Antonella Petrillo,Gerardo Botti,Franco Fulciniti,Giuseppe Palmieri,Paola Queirolo,Paolo Marchetti,Virginia Ferraresi,Gaetana Rinaldi,Maria Pia Pistillo,Gennaro Ciliberto,Nicola Mozzillo,Paolo A. Ascierto +22 more
TL;DR: Changes in some immunological markers between baseline and the fourth ipilimumab infusion appear to be associated with disease control and survival, but verification in prospective clinical trials is required.
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Paolo A. Ascierto,Milena Casula,Jenny Bulgarelli,Marina Pisano,Claudia Piccinini,Luisa Piccin,Antonio Cossu,Mario Mandalà,Pier Francesco Ferrucci,M. Guidoboni,Piotr Rutkowski,Virginia Ferraresi,Ana Arance,Michele Guida,Evaristo Maiello,Helen Gogas,Erika Richtig,Maria Teresa Fierro,Céleste Lebbé,Hildur Helgadottir,P. Queirolo,Francesco Spagnolo,M. Tucci,M. Del Vecchio,Maria Gonzales Cao,Alessandro Marco Minisini,Sabino De Placido,Miguel F. Sanmamed,Domenico Mallardo,Miriam Paone,Maria Grazia Vitale,I. Melero,Antonio M. Grimaldi,Diana Giannarelli,Reinhard Dummer,Vanna Chiarion Sileni,Giuseppe Palmieri +36 more
TL;DR: These long-term survival outcomes confirm immunotherapy as the preferred first-line treatment approach for most patients with BRAF V600-mutant metastatic melanoma, and the biomarker analyses are hypothesis-generating for future investigations of predictors of durable benefit with dual checkpoint blockade and targeted therapy.
29
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
Vito Vanella,Lucia Festino,Claudia Trojaniello,Maria Grazia Vitale,Antonio Sorrentino,Miriam Paone,Paolo A. Ascierto +6 more
TL;DR: The role of BRAF-targeted therapy for advanced melanoma in the immunotherapy era is evaluated, with results suggesting that in patients with BRAF wild-type patients, immunotherapy can be also effective and is regularly used.
23